BOSTON, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics ...
On Monday, H.C. Wainwright analysts assumed coverage of Sensei Biotherapeutics (NASDAQ: SNSE) stock with a Buy rating, setting a price target of $5.00. The analysts highlighted Sensei’s innovative ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results